Reviewed by Michael Gill, B. Sc.
8 Ibrutinib Clinical Trials Near Me
Top Cities for Ibrutinib Clinical Trials
Image of New York in New York.
New York
4Active Trials
TG Therapeutics Investigational Trial SiteTop Active Site
Image of Boston in Massachusetts.
3Active Trials
Massachusetts General HospitalTop Active Site
Ibrutinib Clinical Trials by Phase of Trial
Phase 1 Ibrutinib Clinical Trials
3Active Ibrutinib Clinical Trials
1Number of Unique Treatments
2Number of Active Locations
Most Recent Ibrutinib Clinical Trials

What are Ibrutinib Clinical Trials?

Ibrutinib is a drug given to stop the growth of cancer cells and is on the World Health Organization’s (WHO) list of essential medicines. It inhibits Bruton's tyrosine kinase (BTK), an abnormal protein that causes leukemia cancer cells to multiply. Approved by the FDA in 2013, this drug is used to treat cancers such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia.

Many serious side effects are associated with ibrutinib. These include hemorrhaging, increased infection, heart problems, hypertension, decreased blood counts, secondary cancers and tumor lysis syndrome (TLS), and in extreme cases, sudden death.

Patients taking ibrutinib are asked to avoid grapefruits and Seville oranges, as these fruits increase the amount of ibrutinib in the blood.

Why Is Ibrutinib Being Studied In Clinical Trials?

Since its FDA approval in 2013, new indications of ibrutinib have led to further approvals as clinical trials explored its interaction to treat other types of cancer, such as small lymphocytic lymphoma, relapsed/refractory marginal zone lymphoma, and graft-versus-host disease.

Furthermore, new tablet formulations of ibrutinib with other compounds such as rituximab and obinutuzumab have created more effective medications to treat incurable diseases like Waldenström's macroglobulinemia and the previously untreatable small lymphocytic lymphoma.

Researchers continue to experiment and conduct clinical trials with ibrutinib to develop better, safer treatments for other cancers.

How Does Ibrutinib Treatment Work?

Ibrutinib is not considered a chemotherapy drug. Instead, it is classified as targeted therapy because it only acts on the abnormal protein cells, not the normal ones. However, ibrutinib does inhibit multiple other kinases, such as TEC, EGFR, and TXK, which leads to undesirable toxicities. Therefore the recommended dosage is based on the type and extent of cancer in question.

Dosages are built up and are adjusted as side effects are present. Treatment continues until the disease progresses or an unacceptable level of toxicity is reached.

What Are Some of the Breakthrough Clinical Trials Involving Ibrutinib?

2019: A clinical trial that studied the effectiveness of a combination of ibrutinib-rituximab for chronic lymphocytic leukemia. Results showed that the combined regimen was better than the available chemoimmunotherapy treatment for patients younger than 70 with previously untreated CLL.

2022: A clinical trial sponsored by the Janssen Pharmaceutical Companies of Johnson & Johnson tested the effectiveness of ibrutinib in pediatric patients (ages 1 – 22) with chronic graft-versus-host disease (cGVHD) who had been unresponsive to other therapies. FDA approval was given on preliminary findings, which showed promising results.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Ibrutinib Clinical Trial Research

National Cancer Institute

The National Cancer Institute (NCI) is the US government's principal association for cancer research and training to advance scientific knowledge.

American Association for Cancer Research

American Association for Cancer Research (AACR) is the oldest cancer research organization in the US. Since its conception in 1907, the AACR has strived to foster collaboration among healthcare professionals, communication of knowledge, and funding for further cancer research.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 21st, 2021

Last Reviewed: October 11th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Li M, Bolduc AR, Hoda MN, Gamble DN, Dolisca SB, Bolduc AK, Hoang K, Ashley C, McCall D, Rojiani AM, Maria BL, Rixe O, MacDonald TJ, Heeger PS, Mellor AL, Munn DH, Johnson TS. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. doi: 10.1186/2051-1426-2-21. eCollection 2014. Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, Wu KL, Bishton M, Collins GP, Eliadis P, Peyrade F, Lee Y, Eckert K, Neuenburg JK, Tam CS. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021 Oct 30;14(1):179. doi: 10.1186/s13045-021-01188-x. Sharma MD, Pacholczyk R, Shi H, Berrong ZJ, Zakharia Y, Greco A, Chang CS, Eathiraj S, Kennedy E, Cash T, Bollag RJ, Kolhe R, Sadek R, McGaha TL, Rodriguez P, Mandula J, Blazar BR, Johnson TS, Munn DH. Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. Immunity. 2021 Oct 12;54(10):2354-2371.e8. doi: 10.1016/j.immuni.2021.09.005. Epub 2021 Oct 5.